Trump Administration
Refine Search
Pharmaceutical
A week after US President Donald Trump signed an executive order to bring back the Most Favored Nation (MFN) idea he introduced at the end of his first term, the US Department of Health and Human Services (HHS announced it is proceeding with implementing the order on prescription drug pricing. 20 May 2025
Pharmaceutical
A federal judge in Rhode Island has issued a sweeping order preventing the Trump administration from cutting $11 billion in public health grants, a move that preserves critical funding for 23 states and the District of Columbia as legal proceedings continue. 19 May 2025
Pharmaceutical
In a world where western firms increasingly seek to ingratiate themselves with Middle Eastern leaders and investors, a Saudi company has sought to curry favor with US President Donald Trump in an announcement on pharma manufacturing. 15 May 2025
Pharmaceutical
US Department of Health and Human Services (HHS) Secretary Robert F Kennedy Jr (RFK Jr) has spoken in defence of his proposed HHS budget for fiscal year 2026 to the Senate Health, Education, Labor, and Pensions (HELP) Committee. 15 May 2025
Pharmaceutical
US President Donald Trump released an executive order on May 12 calling for a 30-day negotiation period between the Department of Health and Human Services (HHS) and the biopharma industry, with the threat of a rule from the Centers for Medicare and Medicaid Services (CMS) to lower US drug prices if no deal is reached. 14 May 2025
Pharmaceutical
US pharma stocks regained ground Monday after Donald Trump signed an executive order aiming to slash prescription drug prices, a move that initially rattled investors but left many analysts unconvinced about its impact. 13 May 2025
Pharmaceutical
US President Donald Trump sent shivers through the pharmaceutical industry as he vowed to dramatically reduce the high drug prices that have long been a feature of the US market. 12 May 2025
Pharmaceutical
UK-based pharma major AstraZeneca has started construction on a new manufacturing site for small molecule drugs in Wuxi, a city in East China's Jiangsu province, underscoring its deepening investment in the country. 12 May 2025
Pharmaceutical
The UK government has announced a trade agreement with the USA. The UK-US Economic Prosperity Deal was agreed on Thursday May 8 with further details released on Friday May 9. 9 May 2025
Pharmaceutical
UK pharma major AstraZeneca has suffered a setback in its legal fight to block the US government's efforts to lower prescription drug prices, after a federal appeals court dismissed its challenge to Medicare’s negotiation powers. 9 May 2025
Pharmaceutical
As the US government, under President Donald Trump, is on the verge of announcing significant new tariffs on pharmaceutical imports, Indian drug-maker stocks continue to take a hammering on the bourses. 8 May 2025
Pharmaceutical
Pharmaceutical and Research Manufacturers of America (PhRMA) yesterday submitted comments to the US Department of Commerce on its Section 232 investigation of pharmaceuticals and pharmaceutical ingredients imported to the USA. 8 May 2025
Pharmaceutical
US President Donald Trump has signed an executive order attempting to restore a robust domestic manufacturing base for prescription drugs in the USA. 7 May 2025
Pharmaceutical
In the USA, the Trump administration is urging congressional Republicans to include a “most favored nation” (MFN) policy in their domestic policy package that would tie Medicaid drug payments to the lowest prices paid in other wealthy countries, a White House official confirmed to Inside Health Policy. 5 May 2025
Pharmaceutical
The head of the World Health Organization has issued a stark warning that sudden cuts to global health budgets, including by the USA, are putting years of medical progress in jeopardy. 2 May 2025
Pharmaceutical
A new report from Washington DC-based group No Patient Left Behind argues that foreign governments are underestimating the value of innovative medicines — a claim that adds fuel to the ongoing transatlantic debate on drug pricing and access. 2 May 2025
Pharmaceutical
The US Department of Health and Human Services has announced a sweeping change to the way new vaccines are evaluated, saying it will now require all future vaccines to undergo testing in placebo-controlled trials before being approved for use. 2 May 2025
Pharmaceutical
Shortly after Robert F Kennedy Jr was sworn in as Secretary of Health and Human Services (HHS), US President Donald Trump issued an executive order establishing the Make America Healthy Again Commission. 1 May 2025
Pharmaceutical
AstraZeneca posted a 10% rise in first-quarter revenue to $13.6 billion, supported by strong sales of cancer drugs and biopharmaceuticals. Core earnings per share climbed 21% to $2.49, while reported EPS advanced 34% to $1.88. Pre-tax profits increased 21% year-on-year to $3.4 billion. 29 April 2025
Pharmaceutical
The USA faces a serious risk of measles becoming endemic again, according to a new study modeling the impact of declining childhood vaccination rates, published in JAMA. 28 April 2025
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) yesterday issued a proposed rule that updates payment rates and policy changes in the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System. 14 July 2017
Pharmaceutical
Financial analyst Morningstar has expressed confidence in the strength of the US healthcare market, as “continued abatement of concerns over branded drug prices helps valuations.” 11 July 2017
Pharmaceutical
US Republican attempts to rush through US President Donald Trump’s beleaguered Obamacare replacement look likely to fail, as the Congressional Budget Office found the bill would deny millions of Americans coverage. 27 June 2017
Pharmaceutical
Even as Indian drug firms continue to reel under plans by the Trump administration in the USA to repeal and replace some parts of The Patient Protection and Affordable Care Act, popularly known as Obamacare, four prominent US lawmakers have outlined a number of concerns, including inadequate intellectual property rights protection, reports The Pharma Letter’s India correspondent. 26 June 2017
Pharmaceutical
Republicans have taken the chance to aim further criticism at the Affordable Care Act (ACA) amid US Senate proposals to repeal and replace the act. 23 June 2017
Pharmaceutical
The New York Times published an analysis of a draft Trump executive order on prescription pricing and innovation. US advocacy group consumer rights Public Citizen reviewed portions of the order text in cooperation with the Times. 22 June 2017
Pharmaceutical
Anthem is pulling out of health insurance exchanges in Wisconsin and Indiana, a decision cheered by Republicans as another harbinger of doom for Obamacare. 22 June 2017
Pharmaceutical
As Trump administration officials meet to discuss proposals affecting US drug prices, the consumer rights advocacy group Public Citizen has warned that the plans are likely to make medicines even more unaffordable. 16 June 2017
Pharmaceutical
The PDUFA renewal bill has cleared its penultimate hurdle in the House of Representatives, as the Energy and Commerce Committee this week cleared a final version to be voted on. 9 June 2017
Pharmaceutical
Joe Jimenez, the chief executive of Swiss pharma giant Novartis and chairman-elect of US trade group PhRMA, has said that he expects Donald Trump’s administration to come back with proposals on making prescription drugs more affordable for Americans within three months. 1 June 2017
Pharmaceutical
American lawmakers are reintroducing a bill that would limit the ability of pharmaceutical companies to raise drug prices, with tougher language to prevent medium-term hikes. 16 May 2017
Pharmaceutical
Republicans in the US Congress went into last month’s vote to repeal and replace the Affordable Care Act with guidance from President Trump, effectively: ‘Vote yes or you’re stuck with Obamacare.’ 5 April 2017
Pharmaceutical
There's no doubt about it - last week's failure to pass the American Health Care Act was a painful setback in the fight to repeal and replace Obamacare, wrote Sally Pipes in the Washington Examiner’s Beltway Confidential blog. 31 March 2017
Generics
Research has shown that imports of generic drugs to the USA have fallen since President Trump was elected and took office. 31 March 2017
Pharmaceutical
President Trump's choice to head up the US Food and Drug Administration, Scott Gottlieb, is severing ties with industry in an attempt to put clear blue water between his previous life as a pharmaceutical insider and his new incarnation as FDA Commissioner. 30 March 2017
Pharmaceutical
The International Society of Cellular Therapy (ISCT) believes that the massive and unprecedented budget cuts to US governmental scientific agencies including the (National Institutes of Health (NIH) and National Science Foundation (NSF) proposed by US President Donald Trump, if implemented, will have wide ranging and potentially life threaten in ramifications to science, clinical care and patients in the US and internationally. 24 March 2017
Pharmaceutical
US President Donald Trump has released a budget ‘blueprint’ for 2018 that could have a major impact on the pharmaceutical and healthcare industries in America. 17 March 2017
Pharmaceutical
"Thank God it's Gottlieb" was one analyst’s reaction to the news that President Trump was to pick industry veteran and former FDA deputy commissioner Scott Gottlieb to lead the agency. 13 March 2017
Pharmaceutical
Tuesday night, President Donald Trump gave his joint address to the nation. In it, he suggested that the US Food and Drug Administration prevents a host of new medications and medical devices from hitting the market. 2 March 2017
Pharmaceutical
The mixed messages on drug pricing policy coming from new US President Donald Trump’s administration are starting to harm healthcare stocks, according to an analyst at the independent broker finnCap. 24 February 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze